Latest Updates & Insights

News

Trace the advancements of Allorion Therapeutics through the years

News sorted by year

2024

January 4, 2024

Avenzo Therapeutics announces global license of AVZO-021 (ARTS-021), a potentially best-in-class clinical stage CDK2 inhibitor from Allorion Therapeutics

January 2, 2024

Allorion Therapeutics announces exclusive option and global license agreement for novel preclinical-stage EGFR L858R allosteric inhibitor program with AstraZeneca

2023

October 17, 2023

Allorion Therapeutics presents at the ESMO Conference 2023

Allorion Therapeutics, a clinical-stage biotechnology company that develops novel small molecule drugs for cancer and autoimmune diseases, today announced that one abstract has been selected for poster presentation at the ESMO Conference, taking place from October 20-24, 2023, in Madrid, Spain.

Poster title: ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors

October 11, 2023

Allorion Therapeutics presents preclinical data supporting the development of its CDK2 inhibitor at the AACR-NCI-EORTC International Conference 2023

The preclinical data for ARTS-021 will be presented on October 12 and 13 in the poster sessions at the AACR-NCI-EORTC International Conference 2023 in Boston, Massachusetts.

October 5, 2023

Allorion Therapeutics announces first patient dosed in phase1/2 study of ARTS-021, a potential best in class CDK2 inhibitor, for advanced or metastatic solid tumors

Allorion Therapeutics (Allorion), a clinical-stage biotechnology company dedicated to the discovery and development of next-generation targeted drugs for cancer and autoimmune diseases, announced today the dosing of its first patient in the Phase 1/2 trial of ARTS-021 (NCT05867251). This open-label, first-in-human study is currently ongoing in the US and is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ARTS-021 in adult patients with advanced or metastatic solid tumors.

May 26, 2023

Allorion Therapeutics announces FDA clearance of IND application for ARTS-021

Allorion Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ARTS-021, a CDK2 inhibitor that targets CCNE1-amplified cancers and HR+/HER2- breast cancers. ARTS-021 is a highly selective isoform-specific drug that aims to improve efficacy and overcome resistance in these hard-to-treat cancers.

April 6, 2023

Allorion Therapeutics announces CDE clearance of IND application for ARTS-011

Allorion Therapeutics today announced that the China Center for Drug Evaluation (CDE) has cleared the Company’s Investigational New Drug (IND) application for ARTS-011, a highly selective TYK2 allosteric inhibitor. The Company aims to treat various autoimmune diseases with this novel drug candidate.

April 3, 2023

Allorion Therapeutics appoints Dr. Gregory Berk as Chief Medical Officer

Allorion Therapeutics today announced the appointment of Gregory Berk, M.D. as the Company’s Chief Medical Officer.

March 9, 2023

Allorion Therapeutics announces $50 million series B financing

Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced the completion of $50M Series B financing.

2022

May 6, 2022

Allorion Therapeutics presents preclinical data supporting the development of its TYK2 inhibitor at the IMMUNOLOGY2022 meeting

Allorion Therapeutics named ARTS-011 as the development candidate for its TYK2 program. The preclinical data for ARTS-011 will be presented on May 7 in a poster session at the American Association of Immunologists (AAI) Annual Meeting 2022 in Portland, Oregon.

April 8, 2022

Allorion Therapeutics presents preclinical data supporting the development of its CDK2 inhibitor at the AACR Annual Meeting 2022

Allorion Therapeutics named ARTS-021 as the development candidate for its CDK2 program. The preclinical data for ARTS-021 will be presented on April 12 in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, Louisiana.

2021

ENDPOINTS NEWS | November 23, 2021

A fledgling transpacific biotech grabs a launch round to dive into oncology and autoimmune research

Precision-med biotech Allorion Therapeutics is expanding — and now has tens of millions of dollars more to work with.

November 23, 2021

Allorion Therapeutics announces $40 million series A financing

Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced the completion of $40M Series A financing.

2020

December 1, 2020

Allorion Therapeutics builds internal laboratories

Allorion Therapeutics established laboratories at our Natick and Guangzhou sites and put them into operation, enabling us to carry out biological and chemical experiments in-house. Together with our contract research organizations, these internal experimental facilities will further strengthen our R&D capabilities.